Table 1 Patient characteristics of the control group and each fibrinogen concentrate dose subgroup

Age, years

50 (37–65)

40 (22–56)

41 (26.5–53)

43.5 (28–53.75)

<0.0001

Male, n (%)

153 (79.3)

69 (71.1)

75 (80.6)

39 (75.0)

0.3513

ISS

22 (17–27.5)

29 (25–40)

34 (23–45)

41.5 (33.25–50)

<0.0001

Mortality, n (%)

12 (6.2)

4 (4.1)

5 (5.4)

8 (15.4)

0.0533

Massive transfusion, n (%)

1 (0.5)

8 (8.2)

26 (28.0)

45 (86.5)

<0.0001

FC, g

–

3 (2–4)

6 (6–8)

12 (10.25–15.75)

<0.0001

RBC

 units (total)

0 (0–0)

3 (2–6)

7 (5–10)

15 (11.35–20.75)

<0.0001

  n (%)

25 (13.0)

74 (76.3)

87 (93.5)

52 (100)

<0.0001

 units^b

3 (2–4.5)

4.5 (3–7)

7.0 (5–10)

15.0 (11.25–20.75)

<0.0001

PCC

 IU (total)

0 (0–0)

0 (0–0)

300 (0–1800)

3600 (1800–5400)

<0.0001

  n (%)

5 (2.6)

22 (22.7)

46 (49.5)

50 (96.2)

<0.0001

 IU^b

1800 (1200–4500)

1200 (1150–1800)

1800 (1425–2400)

3600 (1800–5425)

<0.0001

Platelet concentrate

 units (total)

–

0 (0–0)

0 (0–0)

1 (0–2)

<0.0001

  n (%)

–

1 (1.0)

17 (18.2)

28 (53.8)

<0.0001

 units^b

–

2 (2–2)

2 (1.5–2.0)

2.0 (2.0–3.75)

0.2441

FFP

 units (total)

–

–

0 (0–0)

0 (0–0)

<0.0001

  n (%)

–

–

3 (3.2)

10 (19.2)

<0.0001

 units^b

–

–

5 (5–8)

10 (10–13)

0.0097